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Background: Eosinophilic esophagitis (EoE) is an allergic disorder characterized by eosinophil-predominant esophageal
inflammation, which can be ameliorated by food antigen restriction. Though recent studies suggest that changes in
dietary composition may alter the distal gut microbiome, little is currently known about the impact of a restricted diet
upon microbial communities of the oral and esophageal microenvironments in the context of EoE. We hypothesize
that the oral and esophageal microbiomes of EoE patients are distinct from non-EoE controls, that these differences
correspond to changes in esophageal inflammation, and that targeted therapeutic dietary intervention may influence
community structure. Using 16S rRNA gene sequencing, we characterized the bacterial composition of the oral and
esophageal microenvironments using oral swabs and esophageal biopsies from 35 non-EoE pediatric controls and
compared this cohort to samples from 33 pediatric EoE subjects studied in a longitudinal fashion before and after
defined dietary changes.
Results: Firmicutes were more abundant in esophageal samples compared to oral. Proportions of bacterial communities
were significantly different comparing all EoE esophageal microbiota to non-EoE controls, with enrichment of
Proteobacteria, including Neisseria and Corynebacterium in the EoE cohort, and predominance of the Firmicutes
in non-EoE control subjects. We detected a statistically significant difference between actively inflamed EoE biopsies
and non-EoE controls. Overall, though targeted dietary intervention did not lead to significant differences in
either oral or esophageal microbiota, reintroduction of highly allergenic foods led to enrichment in Ganulicatella
and Campylobacter genera in the esophagus.
Conclusions: In conclusion, the esophageal microbiome in EoE is distinct from that of non-EoE controls, with
maximal differences observed during active allergic inflammation.Background
Eosinophilic esophagitis (EoE) is a chronic Th2-mediated
allergic disease of the esophagus characterized by eosino-
philic esophageal infiltration. Its pathogenesis is incom-
pletely understood and likely involves both environmental
and genetic factors [1,2]. In 1995, Kelly et al. made the
seminal observation that an amino acid based elemental
diet led to complete resolution of EoE symptoms, esopha-
geal eosinophilia, and associated endoscopic findings in
pediatric patients [3]. Since this initial finding, other* Correspondence: bushman@mail.med.upenn.edu; wangm@email.chop.edu
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unless otherwise stated.dietary treatment options for EoE have expanded to in-
clude targeted food elimination diets and the empiric
six-food elimination diet (SFED), which has been
shown to be an effective treatment for both children
and adults [4-8]. Food antigens have since been identi-
fied as significant causative agents which trigger immune
responses in EoE [9].
Here, we investigate the relationship of diet, the gut
microbiome, and EoE. The effect of diet upon gut micro-
bial composition has been explored previously in obesity
[10-13] and inflammatory bowel disease (IBD) [10,14].
Relevant to EoE, in which a significant proportion of pa-
tients have IgE-mediated food allergies [2], Stefka et al.
recently showed that the presence of specific gut com-
mensals are protective against development of food allergy
in mouse models [15], potentially through enhancing. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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latory T cells (Tregs) [16].
Several human studies support the association between
altered gut microbiota and the development of atopic dis-
orders early in life [17-19]. However, the effects are not
consistent and were temporary in several studies [20]. Early
colonization with certain bacterial species may influence
the maturation of secretory immunoglobulin A (IgA),
which is associated with protection against development of
food allergies [21]. A reduction in microbial diversity with
increased proportions of E. coli and C. difficile may be
associated with a higher risk of eczema and allergic
sensitization [22]. Clinical studies have indicated that pro-
biotics may have some limited positive effects on atopic
dermatitis, supporting a role for the gut microbiome, but
this has not been confirmed in other studies [20].
Until recently, the esophagus was considered to have
few cultivatable bacterial species [23]. Initial descriptions
of the esophageal microbiome were focused on comparisons
between the oral and the esophageal microbiome [24,25].
Following the development of community profiling using
sequence-based methods, others have shown that the nor-
mal human esophagus has a unique Gram positive (Type I)
dominated bacterial signature, and that shifts to a Gram
negative (Type II) esophageal microbiome may be linked
to gastroesophageal reflux disease (GERD) and Barrett’s
esophagus (BE) [26]. The bacterial profile of the normal
esophagus was subsequently analyzed by Fillon et al.
who used the esophageal string test (EST) to characterizeFigure 1 Flow chart of the experimental design.the esophageal microbiome in children without esophageal
pathology [27]. Using the EST, direct comparisons between
the oral and esophageal microbiomes revealed significant
genera differences between these microenvironments.
To date, there have been no reports characterizing the
esophageal microbiome in EoE. Given the well-established
causal relationship between dietary antigens and EoE dis-
ease activity, we hypothesized that the esophageal micro-
biome in EoE subjects would be distinct from subjects
without EoE, and that there would be differences in the
EoE microbiome following dietary manipulation, which
influences disease activity. In this study, we characterize
the esophageal microbiome in children with and without
EoE using 16S rRNA gene sequencing. Because assess-
ments of EoE disease activity are currently dependent
upon endoscopic surveillance, we also compare the
composition of the oral microbiome to the esophageal
microbiome to determine whether the oral microbiome




Figure 1 summarizes the enrollment and sampling methods
used in this study. Analysis was carried out for 68 subjects
(59 males, 9 females) ranging from 2 to 18 years of
age (Additional file 1: Table S1A and Additional file 2:
Table S1B). All subjects had no history of antibiotic
use for 4 to 6 weeks prior to the procedure, and the
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for 4 to 6 weeks prior to the endoscopy. The two sub-
jects who were not on PPI at the time of endoscopy
were EoE patients who had been previously diagnosed
with EoE while on appropriate PPI therapy.
Thirty-five subjects were designated as non-EoE controls.
Within this group, 29/35 did not have any gastrointestinal
pathology, and 6/35 had mild non-EoE esophagitis. In the
EoE cohort (N = 33), 18 were classified as active EoE (≥15
eosinophils per hpf) and 15 were classified as inactive EoE
(<15 eosinophils per hpf) at the first of two time-points.
Among EoE subjects, 32/33 had no history of systemic or
topical (swallowed) steroid use. Twenty-seven EoE subjects
were enrolled in the longitudinal arm of the study. Seven-
teen EoE subjects with active disease at the first time-point
underwent food elimination challenge (removal of a food(s)
from the SFED), and 10 subjects with inactive disease at
the first time-point added a food(s) into the diet from the
SFED [7]. Food antigen removal or addition was continued
for 4 to 8 weeks prior to the second time-point, at which
point esophageal biopsies and oral swabs were obtained. InFigure 2 Heatmap of esophageal and oral microbiome. Each column corre
in the sequence data. The proportions that each lineage contributed to the
to the right of the figure (values from 0 to 1). Metadata is color-coded at th
(eosinophils per high power field) reported in the biopsies at the time of e
non-EoE controls (C.T1), and EoE subjects had two separate sample collectitotal, 88 oral samples and 78 esophageal samples were
collected for analysis.
The oral and esophageal microbiomes harbor distinct
microbial populations
DNA was purified from biopsy or swab specimens, and
the V1V2 region of the bacterial 16S rRNA gene was
amplified by PCR. Products were sequenced using the
454/Roche method, then sequences condensed into op-
erational taxonomic units of 97% sequence identity and
nearest taxonomy assigned for each (Additional file 3:
Table S2). Figure 2 shows a heatmap of samples, indicat-
ing the types of bacteria detected in each sample. Strong
distinctions between esophageal and oral samples were
observed. Specifically, several members of the phylum
Firmicutes were detected almost exclusively in the biopsy
samples, including Clostridium, Eubacterium, Megasphaera,
Mogibacterium, and Moryella. In addition, the Atopobium
genus of Actinobacteria was predominantly detected in
esophageal biopsy samples and was absent in the majority
of oral swabs.sponds to a specific sample, each row to a type of bacteria identified
full population within each sample are indicated with the color scale
e top, including site sampled, disease status, and number of eos/hpf
ndoscopy. Time-points: Samples were obtained at single time-points in
ons (first: E.T1, second: E.T2).
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Proteobacteria were detected in both sites regardless of
phenotype including the genus Prevotella, Streptococcus,
and Neisseria, respectively. We used a Mantel correlation
and a Procrustes test to determine if there was a statistically
significant correlation between the microbiome present in
the two sites across patients. Both tests showed a signifi-
cant correlation (Mantel correlation = 0.16, P value:
0.008; Procrustes R2: 0.15, P value: 0.009), indicating
sharing of lineages between the oral and esophageal
sites.
The esophageal microbiome in active EoE is characterized
by a distinct microbiome compared to non-EoE controls
We next investigated whether consistent patterns in com-
munity structure could be detected for EoE versus non-
EoE controls within each sample type. We used UniFrac
to calculate distances between all pairs of samples [28,29]
then used tests of the distance matrices to assess relation-
ships among communities from EoE and non-EoE control
subjects. Communities were compared by membership
(presence-absence information) using unweighted UniFrac
and by relative abundance using normalized weighted
UniFrac.
A permanova-based test showed a trend toward a dif-
ference between all EoE and non-EoE control esophageal
samples in community proportions which did not reach
statistical significance (weighted UniFrac distances; Adonis
P values for EoE versus non-EoE control subjects: P =
0.06). This suggested a trend toward differences between
sample groups resulting from differences in bacterial pro-
portions (Additional file 4: Figure S1A,B,C)). Unweighted
UniFrac revealed no differences in community member-
ship (Adonis P values for EoE versus non-EoE control
subjects: P = 0.52). Of note, no differences in member-
ship were found in EoE subjects on a PPI (26/28) when
compared to those not on a PPI (2/28). No significant
differences were observed between EoE and non-EoE con-
trol groups in tests of the oral samples (data not shown).
To determine whether the differences between EoE and
non-EoE microbial proportions were due to disease activ-
ity, we compared samples from individuals with active
EoE, inactive EoE, and non-EoE controls. Using weighted
UniFrac distances, there were statistically significant
differences between active EoE and non-EoE control sub-
jects. Differences between inactive EoE versus non-EoE
controls in weighted UniFrac were not statistically signifi-
cant (Adonis P values for active EoE versus non-EoE con-
trol subjects: 0.037; inactive EoE versus non-EoE control
subjects: 0.062). Comparisons between active EoE and
inactive EoE using weighted UniFrac did not show sig-
nificant differences in either community membership
or relative abundance (disease status Adonis P values:
weighted UniFrac P = 0.404; unweighted UniFrac P = 0.171).Comparisons of bacterial community membership using
unweighted UniFrac showed no statistically significant dif-
ferences (Adonis P values for active EoE versus non-EoE
control: 0.124; inactive EoE × non-EoE control: 0.481).
Together, this suggested that an active, eosinophil-rich, in-
flamed tissue is associated with a distinct shift in relative
abundance of the esophageal microbiota, but not in
community membership. Additionally, richness, Shannon
diversity, and evenness indexes were calculated for each
sample using a Wilcoxon rank-sum test (between non-
EoE controls, active EoE, and inactive EoE subjects) and
significant differences were not detected for any com-
parison (Additional file 3: Table S2 and Additional file 5:
Figure S2).
Because a small number of esophageal samples in the
non-EoE control cohort (six subjects) had histologic evi-
dence of non-eosinophilic esophagitis, we performed a
separate analysis to compare the six non-EoE control sam-
ples with esophagitis to the 25 non-EoE samples without
esophageal inflammation. We did not detect a differ-
ence between subjects with and without inflammation
(unweighted UniFrac P = 0.577 and weighted UniFrac P =
0.455). We performed an additional analysis comparing
EoE to non-EoE controls after removing the six subjects
with non-EoE esophageal inflammation from the control
cohort, and found that though there was a slight reduc-
tion in overall significance [EoE versus non-EoE control
(unweighted UniFrac P = 0.614 and weighted UniFrac P =
0.108), inactive EoE versus non-EoE control (unweighted
UniFrac P = 0.53 and weighted UniFrac P = 0.137) and
active EoE versus non-EoE control (unweighted UniFrac
P = 0.186 and weighted UniFrac P = 0.065)], similar
patterns in esophageal microbiota were observed. Based
upon these findings, we continued to include the six sub-
jects with non-EoE esophagitis as part of the non-EoE
control cohort in the subsequent analyses.
Bacterial lineages associated with EoE and non-EoE
controls
We used the linear discriminant analysis effect size
(LEfSe) test to determine which taxonomic groups were
responsible for the changes observed with weighted UniFrac
in EoE [30]. Taxonomic cladograms of OTUs comparing ac-
tive EoE (21 samples) versus non-EoE control (31 samples)
and inactive EoE (20 samples) versus non-EoE control (31
samples) are shown in Figure 3. The Neisseria genus of the
Proteobacteria was enriched in the EoE samples, as was
Corynebacterium. A relative abundance plot showing the
major genera enriched in active EoE samples compared to
non-EoE controls is shown in Figure 4. These lineages have
been previously implicated in inflammation at other body
sites [31,32], providing a parallel with EoE. The Streptococcus
and Atopobium genera were consistently enriched in
non-EoE control samples. Relative abundance plots for
Figure 3 Comparison of lineages enriched in EoE (28) versus non-EoE control (31) esophageal samples using LEfSe. (A) Comparison of active EoE
(21) versus non-EoE control (31). (B) Comparison of inactive EoE (20) versus non-EoE control (31). The “denovo” indication shows the OTU number.
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EoE are shown in Additional file 6: Figure S3.
Effect of dietary elimination on the esophageal
microbiome in EoE
The SFED is an established treatment for EoE, with
outcomes that compare favorably with both targeted
elimination diets and an elemental diet. Following the
establishment of a SFED, an EGD is typically performed
to establish reduction in esophageal eosinophilia. Once
endoscopic remission is established, groups of foods from
the SFED are added back into the diet and surveillance
EGD is performed several weeks after addition of the new
food group. In our patient cohort, we included subjects
before (time-point 1) and after (time-point 2) a clinically
recommended diet change and hypothesized that dietary
manipulation using foods from the SFED would not only
lead to alterations in the esophageal inflammatory state























Figure 4 Relative abundance plots for Neisseria (A) and Corynebacterium (BA permanova test, using the weighted and unweighted
UniFrac distances, was used to determine if dietary in-
terventions could change the disease status and esopha-
geal microbiome over time,. Dietary intervention did not
have an appreciable global effect on the UniFrac distances
(dietary intervention Adonis P values: weighted UniFrac
P = 0.220; unweighted UniFrac P = 0.450), although this
could be explained by the small effective number of pa-
tients used in this specific analysis. Follow up analysis
using LEfSe was carried out to determine if specific
lineages were differentially represented following spe-
cific dietary changes in EoE [33]. Following the addition
of foods from the SFED, there was an enrichment in
two OTUs of the Granulicatella genus, Carnobacteriaceae
family and the Campylobacter genus in the esophageal
microenvironment (Figure 5) (Granulicatella.denovo347:
P < 0.0363; Granulicatella.denovo3064: P < 0.0358; Granu-
licatella: P < 0.0362; Campylobacter: P < 0.0081. Raw























) in active EoE samples compared to non-EoE controls.
Figure 5 Comparison of lineages enriched under different diet regimens. D = addition of food from the six-food elimination diet (SFED) (10);
OD = open diet (4); RD = restricted diet (13); d = removal of food from the SFED (7).
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Granulicatella and Campylobacter in subjects with a re-
stricted diet who later added an allergenic food as com-
pared to non-EoE controls are shown in Figure 6.
Discussion
In this study, we report a characteristic esophageal micro-
biome in pediatric EoE patients that is influenced by EoE
disease activity and is distinct from the esophageal micro-
biome of non-EoE control subjects. Diet changes did not
detectably influence the composition of the esophageal
microbiome, but the sample was small and heterogeneous,
so further work is needed in this area. We also show a
modest but significant correlation between the oral and
esophageal microbiomes in the cohort used in this study,
regardless of disease status.The esophageal microbiome of non-EoE control sub-
jects showed a predominance of Gram (+) bacteria of
the Streptococcus genus. This is in agreement with previ-
ous findings in control adult subjects [33] and pediatric
subjects [27] without esophageal inflammation. Subjects
included in the study by Yang et al. were predominantly
elderly males [33], whereas the majority of subjects in
the analysis by Fillon et al. were pediatric females [27],
showing consistency between age groups and genders. In
contrast to both studies, the majority of our subjects are
pediatric males with nearly 100% concurrent and docu-
mented PPI use, providing a further indication of the re-
silience of the Streptococcus-dominated microbiome in
the uninflamed esophagus in all age groups and genders.
We observed differences in the esophageal microbiota


















































Figure 6 Relative abundance for Granulicatella (A) and Campylobacter (B) in non-EoE controls and subjects before (RD) and after (D) addition of
food from the SFED.
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ings, members of the genera Corynebacterium and Neis-
seria of the phylum Proteobacteria were enriched in the
setting of esophageal inflammation [24,34,35]. The pres-
ence of Gram (-) organisms including Neisseria has been
reported in previous studies of the esophagus [26,36]
and correlated to inflammatory states. However, in con-
trast to these studies which characterized adult non-EoE
GERD cohorts, ours is the first to explore microbial
communities specifically in EoE. While our results might
suggest a common microbiome shared by all forms of
esophageal inflammation, our study was limited by a
small number of subjects with non-EoE esophageal in-
flammation making it challenging to address if the pres-
ence of non-EoE related inflammation could affect such
correlations. Interestingly, however, the microbial com-
position of our very small cohort of non-EoE controls
with esophageal inflammation was not distinct from those
without esophageal inflammation and was still distinct
from microbiota present in inflamed mucosa of subjects
with EoE. A future larger study specifically comparing the
EoE to non-EoE (GERD) esophageal microbiome would
be highly informative in this regard.
Understanding the cause and effect relationship be-
tween disease state and the microbiome is a subject of
great debate addressed in gnotobiotic studies. Baumler and
colleagues found that Salmonella is increased in gut in-
flammation and proposed that inflammation promotes
proliferation of Salmonella by production of compounds
that Salmonella can use as terminal electron acceptors
[37,38]. In different disease states, gnotobiotic mouse
models have been used to determine whether gut com-
mensals provoke or prevent inflammation. While enteric
bacteria are necessary for the development of murine
colitis [39], germ-free mice are more prone to the de-
velopment of allergen sensitization [40,41]. EoE poses
a unique challenge in this area, as it is clinically char-
acterized by food allergen sensitization and chronic
inflammation.Although we were unable to detect global differences
between subjects on an unrestricted diet and those that
added or removed a highly allergenic food, our LEfSe
analysis revealed a possible enrichment of two genera,
Campylobacter and Granulicatella, following the addition
of a food antigen in the SFED. Campylobacter species
have been associated with inflammatory states of gastro-
intestinal tract including periodontal disease, Barrett’s
esophagus, and IBD [34]. This data suggests addition of
foods leads to increased inflammation and changes in
the microbiome. Others found that seropositivity to
Campylobacter jejuni had a greater association to the
development of atopy [42]. The specific correlation of
these species in the pathogenesis of EoE requires further
study.
The dietary additions and eliminations in this study
were performed according to the clinical recommenda-
tions of the primary gastroenterology/allergy team and
foods which were added or eliminated varied among EoE
subjects. Although an initial goal of our study was to com-
pare the microbiome of EoE subjects before and after an
amino acid based elemental diet, the number of patients
placed on an elemental diet at our institution and others
has declined significantly due to the recently proven effi-
cacy of the SFED [5,8,43]. Therefore, we did not have ad-
equate power to determine the effects of specific foods
upon the differences in the microbiome. The effect of milk
will be fascinating to study in the future as it is the most
common allergen in EoE [8] and has a definite effect on
gut microbiota [44].
Previous studies have characterized the oral microbiome
in the absence of inflammation. The oral microbiomes of
children and adults show a predominance of Firmicutes,
Proteobacteria, Actinobacteria, and Fusobacteria [45]. In
other studies, Streptococcus, Prevotella, Neisseria, Hae-
mophilus, Porphyromonas, Gemella, Rothia, Granulicatella,
Fusobacterium, Actinomyces,Veillonella, and Aggregatibac-
ter are predominant organisms in saliva of healthy subjects
[46]. Comparisons between the oral and esophageal flora
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Streptococcus, Fusobacterium, Neisseria, Haemophilus, and
Prevotella in both sites [25]. This is consistent with our re-
sults in which Streptococcus, Neisseria, and Prevotella were
predominant organisms in both the oral and esophageal
environments.
In the current study, we aimed to study the correlation
between these two microbial populations and determine
whether the 16S rRNA gene tag analysis of the oral mu-
cosa could serve as a biomarker of disease activity. By hav-
ing a single sample per individual, we are able to avoid
autocorrelation issues arising from having two samples
from the same individual. The Mantel correlation and
Procrustes values suggest a weak, albeit significant, cor-
relation between the two datasets (oral and esophageal
biota). We did not detect differences in the oral micro-
biome between active EoE and inactive EoE or non-EoE
control samples, suggesting that in pediatric EoE, bacterial
communities are stable and might not be altered by diet-
ary modification. Thus, the data do not support use of oral
samples in lieu of biopsies for EoE surveillance.
Conclusions
We report distinctive microbiota in patients with active
EoE compared to non-EoE controls. No significant dif-
ferences were seen in inactive EoE samples compared to
non-EoE controls. This difference suggests that the in-
crease in Neisseria and Corynebacterium may be due to
inflammation and not EoE itself. Our subjects were treated
with a variety of dietary interventions. Although this study
is underpowered to detected differences among the treat-
ments, some possible effects were observed that can serve
as hypotheses for future studies.
Methods
Subjects
Subjects enrolled in the study (IRB# 10-007737) were
undergoing diagnostic esophagogastroduodenoscopy (EGD)
at The Children’s Hospital of Philadelphia (CHOP). In-
clusion criteria included an age between 6 months and
21 years, ongoing proton pump inhibitor (PPI) use for
at least 4 weeks prior to EGD, no antibiotic use for at
least 4 weeks prior to EGD, and no other esophageal
disease or chronic inflammatory diseases of the gastro-
intestinal (GI) tract. Non-EoE control subjects showed
no histopathologic abnormalities in the esophagus or
distal GI tract and were not previously diagnosed with
EoE. Both newly diagnosed EoE subjects and subjects
who had previously been diagnosed with EoE based on
clinical guidelines [2] were recruited and analyzed at
two different time-points, before and after a specific diet
change based upon recommendations of the gastro-
enterologist and/or allergist. At the first time-point,
subjects were either on an open diet without restrictions(OD) or a restricted diet (RD) in which specific food
antigens had already been removed based upon sus-
pected causality in the subject’s EoE disease activity.
Prior to the second time-point, selected foods from
the SFED were either added to the diet (D) or elimi-
nated from the diet (d). The experimental plan is
shown in Figure 1, and subject metadata are shown
in Additional file 1: Tables S1A and Additional file 2:
Table S1B.
All EoE subjects were further stratified as active (≥15
eosinophils/high-power field (hpf )) or inactive (<15
eosinophils/hpf ) based on EoE diagnostic criteria [2].
After written informed consent and/or assent was ob-
tained, oral swabs from the inner cheeks, hard palate,
and distal third of the tongue were collected using a
sterile microbrush and stored on dry ice prior to pro-
cessing. Esophageal biopsies from the distal third of
the esophagus were collected during EGD using sterile
forceps and immediately placed on dry ice.
Sample processing
Oral swabs and esophageal biopsies were separately stored
in sterile Eppendorf tubes on dry ice, then transferred
to a −80°C freezer until processing. Bacterial DNA ex-
traction from oral swabs and esophageal biopsies was
performed in a sterile tissue culture hood using the MoBio
PowerSoil DNA Isolation Kit (Mo Bio Laboratories,
Carlsbad, CA, USA) and DNeasy Blood and Tissue Kit
(Qiagen, Maryland, USA), respectively.
For bacterial DNA isolation from oral swabs, sterile
scissors were used to cut the swab tip into the MoBio
Power-Bead tube, and DNA was isolated according to
manufacturer’s instructions. For extraction of bacterial
DNA from biopsies, samples were incubated in a lysozyme
solution containing 20 mg/ml lysozyme in 180 μl of 20
mM Tris-HCl (pH 8.0), 2 mM EDTA, and 1.2% Triton
X-100, at 95°C for 5 min and 37°C for 60 min, followed
by manufacturer’s instructions to complete DNA ex-
traction. DNA was amplified by adding 10 μl of DNA
to 40 μl of PCR mixture containing 5 μl of 10× PCR
Buffer (Invitrogen, Carlsbad, CA, USA), 200 μM each
dNTP, 50 pmol barcoded primer [47], and 2 units of
AccuPrime TaqDNA polymerase. Reactions were per-
formed on an Eppendorf Mastercycler pro Model 6325
(Hauppauge, NY, USA) using the following conditions:
initial denaturation at 95°C for 5 min followed by 30
cycles (30 for swabs and 35 for biopsies) of 95°C × 30 s,
56°C × 30 s, and 72°C × 1 min 30 s. The reaction was
terminated after an 8-min extension at 72°C. The amp-
lification reactions were performed in quadruplicate.
Products were pooled and bead purified using magnetic
beads from Angencourt AMPure XP (Beckman Coulter
Inc., Brea, CA, USA) and a DynaMag-Spin Magnetic
Particle Concentrator (Invitrogen Dyna AS, Oslo, Norway).
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Pooled DNA samples were sequenced using the Roche/454
Genome sequencer or Genome Sequencer Junior plat-
forms (454, Branford, CT, USA). The sequences obtained
were processed using the QIIME software package [48]
using default parameters and the R statistical package [49]
unless otherwise stated. Briefly, sequences were collapsed
into operational taxonomic units (OTUs) at 97% similar-
ity, from which a representative sequence was selected.
These representative sequences were used for taxonomic
classification, OTU table creation, and UniFrac calcula-
tions. Samples yielding less than 300 sequences and OTUs
containing only one sequence across all samples were re-
moved from further analysis [50]. A multiple rarefaction
procedure was implemented as follows to increase the
confidence that the community assessed was a representa-
tive of the actual community present in the sample and to
remove biases caused by uneven sampling depth across all
samples: after filtering, the remaining samples were rar-
efied down to 500 sequences 100 times, and an average of
the sequence counts for these rarefactions was used. The
final OTU table was filtered to contain OTUs which
were present in at least ten samples (Additional file 3:
Table S2).
Statistical analysis
Global microbiome changes were analyzed using weighted
and unweighted UniFrac distances across all samples.
Statistical differences were assessed using the Adonis test
implemented in the R package Vegan v2.0-10 [51]. Adonis
permutations were restricted using strata to account
for the repeated measure nature of the data when
testing the disease status and dietary intervention var-
iables. Richness and evenness were also assessed using
the Vegan Package. For the dietary intervention test,
only samples within diets corresponding to open diet
(N = 4), restricted diet (N = 13), elimination (N = 7),
and reintroduction of an allergenic food (N = 10)
were considered in order to reduce variability in the
dataset. OTU differences across groups were analyzed
using LEfSe [30]. Only one sample per subject per site
of sampling was used in the statistical tests unless
otherwise stated.
Additional files
Additional file 1: Table S1A. Characteristics of non-EoE control pediatric
subjects. Data include site of sample collection, disease status, symptoms,
demographics, history of atopic disease, diet, endoscopic findings, histologic
findings, and peak eosinophils per high power field.
Additional file 2: Table S1B. Characteristics of EoE pediatric subjects.
Data includes site of sample collection, time-point of data collection,
disease status (active ≥ 15 eosinophils/high power field (hpf)) or inactive
(<15 eosinophils/hpf), symptoms, demographics, history of atopic disease,
specific dietary interventions, duration of intervention, endoscopic findings,
histologic findings, and peak eosinophils per hpf.Additional file 3: Table S2. OTU table with taxa, sequence numbers
per samples, Shannon diversity, and evenness values. Bacterial DNA
sequences were condensed into OTUs of 97% sequence identity, and
nearest taxa were assigned to each sequence. OTUs listed were present
in at least ten samples.
Additional file 4: Figure S1. Ordination comparing EoE and non-EoE
control samples. (A) Pairwise distances were calculated between samples,
then data plotted using Principal Coordinates Analysis. The centroid of
the non-EoE control samples and the EoE samples are indicated on the
plot. Lines connect each sample to the appropriate centroid. (B) and (C)
show the same plot color-coded according the proportion of Neisseria
and Streptococcus present in each sample.
Additional file 5: Figure S2. Richness, Shannon diversity, and evenness
indexes. Comparisons between control, inactive EoE, and active EoE using
a Wilcoxon rank-sum test.
Additional file 6: Figure S3. Relative abundance for genus Streptococcus
and Atopobium in active EoE versus non-EoE controls.
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